MNRAP: Screening Process Step 1 - Minnesota Dept. of Health

Minnesota Resource Allocation Platform for COVID-19 Treatment
Screening Process
Step 1 of 3

Review the Emergency Use Authorization (EUA) information for these drug treatments.

Drug treatments available through MNRAP are authorized by the FDA under an EUA, meaning they have not been fully FDA-approved. In an emergency, like a pandemic, it may not be possible to have all the evidence that the FDA would usually have before approving a treatment. In this situation, the FDA can make a judgment to release drug treatments for use before it's fully approved. If there's evidence that strongly suggests that patients have benefited from a treatment, the agency can issue an EUA to make it available. An EUA does not mean that a treatment has not been studied, or that a treatment is experimental. Receiving a drug under an EUA is different than participating in a clinical trial.

If you are referred for a treatment, you will be given additional information about the treatment at your appointment. You will also be asked whether you consent to receive the treatment. You may choose to opt out at any time. If you are unsure about whether you should receive one of these treatments, please speak to your health care provider and read through the patient fact sheets for more information.

Keep in mind that the monoclonal antibody treatments currently available through MNRAP have the same eligibility criteria. Which one you receive will be up to the health care facility where your referral is sent. As more treatment options become available, patients may be referred for specific treatments depending on which one they are most likely to benefit from.

Read more about Emergency Use Authorizations.

Next: Screening Process
Step 1 of 3

Return to:

Updated Monday, 27-Sep-2021 14:11:31 CDT